FTO modifies the m6A level of MALAT and promotes bladder cancer progression. Issue 2 (1st February 2021)
- Record Type:
- Journal Article
- Title:
- FTO modifies the m6A level of MALAT and promotes bladder cancer progression. Issue 2 (1st February 2021)
- Main Title:
- FTO modifies the m6A level of MALAT and promotes bladder cancer progression
- Authors:
- Tao, Le
Mu, Xingyu
Chen, Haige
Jin, Di
Zhang, Ruiyun
Zhao, Yuyang
Fan, Jie
Cao, Ming
Zhou, Zhihua - Abstract:
- Abstract: Background: Nearly a half million people around the world are diagnosed with bladder cancer each year, and an incomplete understanding of its pathogenicity and lack of efficient biomarkers having been discovered lead to poor clinical management of bladder cancer. Fat mass and obesity‐associated protein (FTO) is a critical player in carcinogenesis. We, here, explored the role of FTO and unraveled the mechanism of its function in bladder cancer. Methods: Identification of the correlation of FTO with bladder cancer was based on both bioinformatics and clinical analysis of tissue samples collected from a cohort of patients at a hospital and microarray data. Gain‐of‐function and loss‐of‐function assays were conducted in vivo and in vitro to assess the effect of FTO on bladder carcinoma tumor growth and its impact on the bladder carcinoma cell viability. Moreover, the interactions of intermediate products were also investigated to elucidate the mechanisms of FTO function. Results: Bladder tumor tissues had increased FTO expression which correlated with clinical bladder cancer prognosis and outcomes. Both in vivo and in vitro, it played the function of an oncogene in stimulating the cell viability and tumorigenicity of bladder cancer. Furthermore, FTO catalyzed metastasis‐associated lung adenocarcinoma transcript 1 (MALAT1) demethylation, regulated microRNA miR‐384 and mal T cell differentiation protein 2 (MAL2) expression, and modulated the interactions among theseAbstract: Background: Nearly a half million people around the world are diagnosed with bladder cancer each year, and an incomplete understanding of its pathogenicity and lack of efficient biomarkers having been discovered lead to poor clinical management of bladder cancer. Fat mass and obesity‐associated protein (FTO) is a critical player in carcinogenesis. We, here, explored the role of FTO and unraveled the mechanism of its function in bladder cancer. Methods: Identification of the correlation of FTO with bladder cancer was based on both bioinformatics and clinical analysis of tissue samples collected from a cohort of patients at a hospital and microarray data. Gain‐of‐function and loss‐of‐function assays were conducted in vivo and in vitro to assess the effect of FTO on bladder carcinoma tumor growth and its impact on the bladder carcinoma cell viability. Moreover, the interactions of intermediate products were also investigated to elucidate the mechanisms of FTO function. Results: Bladder tumor tissues had increased FTO expression which correlated with clinical bladder cancer prognosis and outcomes. Both in vivo and in vitro, it played the function of an oncogene in stimulating the cell viability and tumorigenicity of bladder cancer. Furthermore, FTO catalyzed metastasis‐associated lung adenocarcinoma transcript 1 (MALAT1) demethylation, regulated microRNA miR‐384 and mal T cell differentiation protein 2 (MAL2) expression, and modulated the interactions among these processes. Conclusions: The interplay of these four clinically relevant factors contributes to the oncogenesis of bladder cancer. FTO facilitates the tumorigenesis of bladder cancer through regulating the MALAT/miR‐384/MAL2 axis in m6A RNA modification manner, which ensures the potential of FTO for serving as a diagnostic or prognostic biomarker in bladder cancer. Abstract : FTO stimulates tumor growth of bladder cancer through regulating MALAT1 methylation. MALAT1 and MAL2 interact with miR‐384 for regulating tumor growth of bladder cancer. FTO promotes bladder cancer tumor growth via MALAT1/miR‐384/MAL2 axis. … (more)
- Is Part Of:
- Clinical and translational medicine. Volume 11:Issue 2(2021)
- Journal:
- Clinical and translational medicine
- Issue:
- Volume 11:Issue 2(2021)
- Issue Display:
- Volume 11, Issue 2 (2021)
- Year:
- 2021
- Volume:
- 11
- Issue:
- 2
- Issue Sort Value:
- 2021-0011-0002-0000
- Page Start:
- n/a
- Page End:
- n/a
- Publication Date:
- 2021-02-01
- Subjects:
- bladder cancer -- cell viability -- FTO -- MAL2 -- MALAT1 -- miR‐384 -- N6‐methyladenosine mRNA modification -- tumor growth
Clinical medicine -- Periodicals
Medicine, Experimental -- Periodicals
Medical innovations -- Periodicals
Molecular biology -- Periodicals
Pathology, Molecular -- Periodicals
616.027 - Journal URLs:
- https://onlinelibrary.wiley.com/loi/20011326 ↗
http://www.clintransmed.com/content ↗
http://www.biomedcentral.com/journals/#C ↗
http://www.springer.com/gb/ ↗ - DOI:
- 10.1002/ctm2.310 ↗
- Languages:
- English
- ISSNs:
- 2001-1326
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 15912.xml